Protalix BioTherapeutics
PLX
30 hedge funds and large institutions have $1.3M invested in Protalix BioTherapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 5 closing their positions.
648% more call options, than puts
Call options by funds: $1.63M | Put options by funds: $218K
1% more capital invested
Capital invested by funds: $1.29M → $1.3M (+$9.36K)
0.14% less ownership
Funds ownership: 2.67% → 2.54% (-0.14%)
6% less funds holding
Funds holding: 32 → 30 (-2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$152K |
| 2 |
Renaissance Technologies
New York
|
+$120K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$70.1K |
| 4 |
CPA
Capital Performance Advisors
Walnut Creek,
California
|
+$30.4K |
| 5 |
Two Sigma Investments
New York
|
+$29.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$259K |
| 2 |
Jane Street
New York
|
-$72.1K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$38.2K |
| 4 |
Morgan Stanley
New York
|
-$18.4K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APA
26
American Portfolios Advisors
Holbrook,
New York
| $545 | – | – | – |
|
|
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $273 | -$994 | -850 | -77% |
|
|
PF
28
Phoenix Financial
Givatayim,
Israel
| – | -$259K | -244,113 | Closed |
|
|
29
Group One Trading
Chicago,
Illinois
| – | -$38.2K | -32,646 | Closed |
|
|
30
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$14.2K | -12,119 | Closed |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| – | -$7K | -6,465 | Closed |
|
32
JP Morgan Chase
New York
| – | -$856 | -732 | -65% |
|
PLX Hedge Fund Activity: Q2 2022 in Review
30 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2022, worth a combined $1.3M — up 0.73% from $1.29M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PLX and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $152K. The largest seller was Phoenix Financial, exiting entirely with an estimated $259K sold.
- 30 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2022, down from 32 in Q1 2022.
- Funds reported $1.3M of Protalix BioTherapeutics stock for Q2 2022, up 0.73% quarter-over-quarter.
- 4 funds opened new Protalix BioTherapeutics positions in Q2 2022 and 5 closed out, a net change of -1 holder.
- The largest Protalix BioTherapeutics buyer in Q2 2022 was Bridgeway Capital Management, an estimated $152K added.
- The largest Protalix BioTherapeutics seller in Q2 2022 was Phoenix Financial, an estimated $259K sold.
Based on aggregated 13F filings for Q2 2022.